BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;114:96-102. [PMID: 29173773 DOI: 10.1016/j.lungcan.2017.11.005] [Cited by in Crossref: 78] [Cited by in F6Publishing: 88] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Chaudhari R, Fong LW, Tan Z, Huang B, Zhang S. An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opin Drug Discov 2020;15:1025-44. [PMID: 32452701 DOI: 10.1080/17460441.2020.1767063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Falla-Martinez JC, Espinosa D, Baena JC, Rodriguez LX, Sua LF, Zambrano AR. An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. J Med Case Rep 2019;13:144. [PMID: 31088573 DOI: 10.1186/s13256-019-2075-y] [Reference Citation Analysis]
3 Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl NB, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol 2020;27:e146-55. [PMID: 32489263 DOI: 10.3747/co.27.6007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ulmer B, Odenthal M, Buettner R, Roth W, Kloth M. Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. NPJ Syst Biol Appl 2022;8:2. [PMID: 35046405 DOI: 10.1038/s41540-021-00211-8] [Reference Citation Analysis]
5 Wu L, Zhong W, Li A, Qiu Z, Xie R, Shi H, Lu S. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Ann Transl Med 2021;9:950. [PMID: 34350265 DOI: 10.21037/atm-21-2823] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol 2022:S0923-7534(22)00112-0. [PMID: 35176458 DOI: 10.1016/j.annonc.2022.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. Cancer Res Treat 2019;51:623-31. [PMID: 30049203 DOI: 10.4143/crt.2018.151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
8 Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F. Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. Current Oncology 2022;29:255-66. [DOI: 10.3390/curroncol29010024] [Reference Citation Analysis]
9 Taniguchi Y, Takeda M, Tamiya A, Kasai T, Atagi S. Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer. Annals of Oncology 2018;29:2262-3. [DOI: 10.1093/annonc/mdy401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kujtan L, Subramanian J. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 2019;19:547-59. [PMID: 30913927 DOI: 10.1080/14737140.2019.1596030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
11 Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018;7. [PMID: 29890761 DOI: 10.3390/jcm7060144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
12 Gao X, Wei XW, Zheng MY, Chen ZH, Zhang XC, Zhong WZ, Yang JJ, Wu YL, Zhou Q. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. J Thorac Dis 2020;12:5822-32. [PMID: 33209414 DOI: 10.21037/jtd-20-1630] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zhao Y, Zhai L, Deng L, Halmos B, Cheng H. Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review. Clin Lung Cancer 2021;22:e466-9. [PMID: 32693946 DOI: 10.1016/j.cllc.2020.06.017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Scodes S, Cappuzzo F. Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Expert Rev Respir Med 2020;14:565-76. [PMID: 32233809 DOI: 10.1080/17476348.2020.1746646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wei J, Meng P, Terpstra MM, van Rijk A, Tamminga M, Scherpen F, Ter Elst A, Alimohamed MZ, Johansson LF, Stigt J, Gijtenbeek RPG, van Putten J, Hiltermann TJN, Groen HJM, Kok K, van der Wekken AJ, van den Berg A. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC. Target Oncol 2021;16:215-26. [PMID: 33606136 DOI: 10.1007/s11523-021-00798-2] [Reference Citation Analysis]
16 Xu H, Yang G, Li W, Li J, Hao X, Xing P, Yang Y, Wang Y. EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. Front Oncol 2021;11:713483. [PMID: 34540680 DOI: 10.3389/fonc.2021.713483] [Reference Citation Analysis]
17 Taniguchi Y, Tamiya A, Ishii S, Atagi S. Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations. Annals of Oncology 2018;29:1331-3. [DOI: 10.1093/annonc/mdy087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Xu Z, Qin F, Yuan L, Wei J, Sun Y, Qin J, Deng K, Zheng T, Li S. EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma. Front Oncol 2021;11:691915. [PMID: 34447695 DOI: 10.3389/fonc.2021.691915] [Reference Citation Analysis]
19 Shah R, Lester JF. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. Clin Lung Cancer 2020;21:e216-28. [PMID: 32014348 DOI: 10.1016/j.cllc.2019.12.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
20 Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer 2020;145:186-94. [PMID: 32336530 DOI: 10.1016/j.lungcan.2020.03.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
21 Remon J, Hendriks LE, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treatment Reviews 2020;90:102105. [DOI: 10.1016/j.ctrv.2020.102105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
22 Cao Z, Liao Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: The way forward? Cancer Lett 2019;459:30-40. [PMID: 31128213 DOI: 10.1016/j.canlet.2019.05.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
23 Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Oncologist 2019;24:e1070-81. [PMID: 30902917 DOI: 10.1634/theoncologist.2018-0572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
24 Ma C, Yang X, Xing W, Yu H, Si T, Guo Z. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Thorac Cancer 2020;11:588-93. [PMID: 31944608 DOI: 10.1111/1759-7714.13300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
25 Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol 2021;16:764-73. [PMID: 33333327 DOI: 10.1016/j.jtho.2020.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
26 Evrard SM, Taranchon-clermont E, Rouquette I, Murray S, Dintner S, Nam-apostolopoulos Y, Bellosillo B, Varela-rodriguez M, Nadal E, Wiedorn KH, Melchior L, Andrew E, Jones M, Ridgway J, Frykman C, Lind L, Rot M, Kern I, Speel EJ, Roemen GM, Trincheri N, Freiberger SN, Rechsteiner M. Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer. The Journal of Molecular Diagnostics 2019;21:1010-24. [DOI: 10.1016/j.jmoldx.2019.06.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
27 Tamura T, Kawakado K, Makimoto G, Nakanishi M, Kuyama S. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report. Thorac Cancer 2021;12:1770-4. [PMID: 33942527 DOI: 10.1111/1759-7714.13941] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Lin T, Fu Y, Zhang X, Gu J, Ma X, Miao R, Xiang X, Niu W, Qu K, Liu C, Wu Q. A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer. Aging (Albany NY) 2018;10:2356-66. [PMID: 30205363 DOI: 10.18632/aging.101550] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
29 Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl) 2019;10:1-10. [PMID: 30774491 DOI: 10.2147/LCTT.S181406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
30 Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 2021;11:1688-99. [PMID: 33632775 DOI: 10.1158/2159-8290.CD-20-1598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
31 Liu S, Dong Z, Wu S, Xie Z, Yan L, Li Y, Yan H, Su J, Yang J, Zhou Q, Zhong W, Tu H, Yang X, Zhang X, Wu Y. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer 2018;125:86-92. [DOI: 10.1016/j.lungcan.2018.09.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
32 Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R, Han B. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09409-3] [Reference Citation Analysis]
33 Hakozaki T, Yomota M. Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review. Onco Targets Ther 2019;12:745-8. [PMID: 30774361 DOI: 10.2147/OTT.S190034] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lin R, Chen R, Chen Z, Hu L, Guo W, Zhang Z, Lin L, Chen H. Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review. Front Oncol 2021;11:731572. [PMID: 34540698 DOI: 10.3389/fonc.2021.731572] [Reference Citation Analysis]
35 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med 2019;8:1521-9. [PMID: 30790471 DOI: 10.1002/cam4.2037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
37 Liu R, Zhang Y, Ding Y, Zhang S, Pan L. Characteristics of TGFBR1-EGFR-CTNNB1-CDH1 Signaling Axis in Wnt-Regulated Invasion and Migration in Lung Cancer. Cell Transplant 2020;29:963689720969167. [PMID: 33231090 DOI: 10.1177/0963689720969167] [Reference Citation Analysis]
38 Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, Wang W, Guo H, Wang K, Zhang L. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer 2019;19:595. [PMID: 31208370 DOI: 10.1186/s12885-019-5820-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
39 Bourien H, Lespagnol A, Campillo-Gimenez B, Felten-Vinot I, Metges JP, Corre R, Lesimple T, le Marechal C, Boussemart L, Kammerer-Jacquet SF, le Gall E, Denoual F, de Tayrac M, Galibert MD, Mosser J, Edeline J. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. Int J Clin Oncol 2020;25:1234-41. [PMID: 32215806 DOI: 10.1007/s10147-020-01661-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Bai R, Chen X, Song W, Tian H, Cui J. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. J Cancer Res Clin Oncol 2021. [PMID: 34698913 DOI: 10.1007/s00432-021-03840-y] [Reference Citation Analysis]
41 Leclair N, Calafiore R, Wu Q, Wolansky L, Bulsara KR. Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: Case report. Neurochirurgie 2020;66:477-83. [PMID: 33091460 DOI: 10.1016/j.neuchi.2020.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Zhou W, Zhang W, Han B. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:118-26. [PMID: 32093456 DOI: 10.3779/j.issn.1009-3419.2020.02.07] [Reference Citation Analysis]
43 Miyawaki E, Murakami H, Mori K, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Takahashi T. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. Jpn J Clin Oncol 2020;50:617-22. [PMID: 32211792 DOI: 10.1093/jjco/hyaa033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Qin Q, Li X, Liang X, Zeng L, Wang J, Sun L, Zhong D. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). Thorac Cancer 2020;11:2389-97. [PMID: 32677256 DOI: 10.1111/1759-7714.13521] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
45 Caliman E, Petreni P, Brugia M, Antonuzzo L, Mazzoni F. In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations". Clin Lung Cancer 2020;21:e363-5. [PMID: 32143968 DOI: 10.1016/j.cllc.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
47 Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol 2019;15:637-52. [PMID: 30404555 DOI: 10.2217/fon-2018-0736] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
48 Liu W, Zhuang C, Huang T, Yang S, Zhang M, Lin B, Jiang Y. Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression. Mol Genet Genomic Med 2020;8:e1521. [PMID: 33155773 DOI: 10.1002/mgg3.1521] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer Med 2020;9:12-8. [PMID: 31692291 DOI: 10.1002/cam4.2652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Karlsen EA, Kahler S, Tefay J, Joseph SR, Simpson F. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells 2021;10:1206. [PMID: 34069119 DOI: 10.3390/cells10051206] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Reference Citation Analysis]
52 Huang CH, Ju JS, Chiu TH, Huang AC, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int J Cancer 2021. [PMID: 34558665 DOI: 10.1002/ijc.33821] [Reference Citation Analysis]
53 Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X, Huang Z, Fan Y. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Lung Cancer 2020;142:98-105. [PMID: 32120230 DOI: 10.1016/j.lungcan.2020.02.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
54 Lee JH, Lin WC, Wen TK, Wang C, Lin YT. Inhibiting two cellular mutant epidermal growth factor receptor tyrosine kinases by addressing computationally assessed crystal ligand pockets. Future Med Chem 2019;11:833-46. [PMID: 30724109 DOI: 10.4155/fmc-2018-0525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Cardona AF, Rojas L, Zatarain-barrón ZL, Freitas HC, Granados ST, Castillo O, Oblitas G, Corrales L, Castro CD, Ruiz-patiño A, Martín C, Pérez MA, González L, Chirinos L, Vargas C, Carranza H, Otero J, Rodriguez J, Rodriguez J, Archila P, Lema M, Acosta Madiedo J, Karachaliu N, Wills B, Pino LE, de Lima V, Rosell R, Arrieta O. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer 2018;125:265-72. [DOI: 10.1016/j.lungcan.2018.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
56 Kim YJ, Oremus M, Chen HH, McFarlane T, Fearon D, Horton S. Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. J Comp Eff Res 2021;10:193-206. [PMID: 33543641 DOI: 10.2217/cer-2020-0173] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Wu SG, Yu CJ, Yang JC, Shih JY. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.Ther Adv Med Oncol. 2020;12:1758835920946156. [PMID: 32843903 DOI: 10.1177/1758835920946156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Ma C, Zhang J, Tang D, Ye X, Li J, Mu N, Li Z, Liu R, Xiang L, Huang C, Jiang R. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. Front Oncol 2020;10:224. [PMID: 32195178 DOI: 10.3389/fonc.2020.00224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
59 Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D, Ou X, Xu Y, Tang Y, Ou X, Hu C, Ding X, Luo P, Yu S. Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. Pathol Oncol Res 2021;27:602726. [PMID: 34257561 DOI: 10.3389/pore.2021.602726] [Reference Citation Analysis]
60 Simionato F, Calvetti L, Cosci M, Scarparo S, Aprile G. Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation. Onco Targets Ther 2020;13:12027-31. [PMID: 33262603 DOI: 10.2147/OTT.S280933] [Reference Citation Analysis]
61 Xu CW, Wang WX, Wang D, Wang QM, Pu XX, Zhu YC, Huang JH, Yu ZY, Cui ZL, Chen XH, Li JL, Fang Y, Wang H, Zhuang W, Lan SJ, Cai X, Zhang YB, Gao WB, Wang LP, She KL, Rao CZ, Zhou YF, Fang MY, Miao LY, Lei L, Lv TF, Song Y. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res 2020;9:1853-61. [PMID: 33209607 DOI: 10.21037/tlcr-20-382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Ullas B, Shrinidhi N, Mansi S, Narayan S, Parveen J, Surender D, Joslia JT, Anurag M. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. J Cancer Res Clin Oncol 2022. [PMID: 35581383 DOI: 10.1007/s00432-022-04033-x] [Reference Citation Analysis]
63 Liu SY, Sun H, Zhou JY, Jie GL, Xie Z, Shao Y, Zhang X, Ye JY, Chen CX, Zhang XC, Zhou Q, Yang JJ, Wu YL. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark Res 2020;8:22. [PMID: 32607238 DOI: 10.1186/s40364-020-00199-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
64 Tsai MJ, Hung JY, Lee MH, Kuo CY, Tsai YC, Tsai YM, Liu TC, Yang CJ, Huang MS, Chong IW. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancers (Basel). 2018;10. [PMID: 30428509 DOI: 10.3390/cancers10110434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
65 Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res 2020;9:2982-91. [PMID: 35117654 DOI: 10.21037/tcr.2020.03.10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
66 Hirose T, Ikegami M, Endo M, Matsumoto Y, Nakashima Y, Mano H, Kohsaka S. Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer 2021;152:135-42. [PMID: 33395611 DOI: 10.1016/j.lungcan.2020.12.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Li T, Wang S, Ying J, Wang Y, Hu X, Hao X, Xu Z, Xing P, Li J. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thorac Cancer 2021;12:2924-32. [PMID: 34549528 DOI: 10.1111/1759-7714.14156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS One 2021;16:e0247620. [PMID: 33684140 DOI: 10.1371/journal.pone.0247620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
69 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
70 Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM; Study Group for the Uncommon EGFR Mutations in Spain. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clin Lung Cancer 2020;21:428-436.e2. [PMID: 32461037 DOI: 10.1016/j.cllc.2020.04.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
71 Zeng Y, Guo T, Zhou Y, Zhao Y, Chu L, Chu X, Yang X, Ni J, Zhu Z. Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters. BMC Cancer 2022;22:198. [PMID: 35189835 DOI: 10.1186/s12885-022-09245-5] [Reference Citation Analysis]
72 Park E, Shim HS. Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing. Cancer Res Treat 2020;52:543-51. [PMID: 31726498 DOI: 10.4143/crt.2019.305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Du W, Wo Y, Lu T, Wang Y, Jiao W. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations]. Zhongguo Fei Ai Za Zhi 2019;22:590-9. [PMID: 31526464 DOI: 10.3779/j.issn.1009-3419.2019.09.07] [Reference Citation Analysis]
74 Li X, Zhao Z, Yi S, Ma L, Li M, Liu M, Zhang Y, Liu G. Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma. J Transl Med 2018;16:183. [PMID: 29973197 DOI: 10.1186/s12967-018-1561-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci 2019;20:E1431. [PMID: 30901844 DOI: 10.3390/ijms20061431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
76 Tan J, Hu C, Deng P, Wan R, Cao L, Li M, Yang H, Gu Q, An J, Jiang J. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Front Oncol 2021;11:646577. [PMID: 34513661 DOI: 10.3389/fonc.2021.646577] [Reference Citation Analysis]
77 Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. Future Oncol 2020;16:2569-86. [PMID: 32927981 DOI: 10.2217/fon-2020-0320] [Reference Citation Analysis]
78 Chang L, Lim C, Chang L, Chen K, Shih J, Yu C. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. European Journal of Cancer 2019;119:77-86. [DOI: 10.1016/j.ejca.2019.06.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
79 Yang J, Li Y, Ma B, Xie H, Chen L, Gao X, He W. Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study. Transl Cancer Res 2020;9:7562-71. [PMID: 35117356 DOI: 10.21037/tcr-20-1675] [Reference Citation Analysis]
80 Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, Ellidokuz H, Basbinar Y. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep 2020;13:2. [PMID: 32509305 DOI: 10.3892/br.2020.1308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 He C, He Y, Luo H, Zhang M, Wu J, He X, Fu Y, Chen W, Zou J. Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon�21 L858R subsequent to treatment with EGFR‑TKIs. Oncol Lett 2019. [DOI: 10.3892/ol.2019.10348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Ikeuchi H, Hirose T, Ikegami M, Takamochi K, Suzuki K, Mano H, Kohsaka S. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene 2022. [PMID: 35304574 DOI: 10.1038/s41388-022-02263-4] [Reference Citation Analysis]
83 Wu Z, Chen S, Du X, Wu Y, Xie X. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis. J Clin Pharm Ther 2021;46:310-8. [PMID: 33031574 DOI: 10.1111/jcpt.13281] [Reference Citation Analysis]
84 Chen K, Pan G, Cheng G, Zhang F, Xu Y, Huang Z, Fan Y. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions. Thorac Cancer 2021;12:218-26. [PMID: 33210451 DOI: 10.1111/1759-7714.13748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
85 Leipert J, Hammerschmidt S, Geßner C. Medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. Pneumologe 2019;16:397-409. [DOI: 10.1007/s10405-019-00284-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Singh V, Nambirajan A, Malik PS, Thulkar S, Pandey RM, Luthra K, Arava S, Ray R, Mohan A, Jain D. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. Lung Cancer 2020;149:53-60. [PMID: 32971387 DOI: 10.1016/j.lungcan.2020.07.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. Cancer Sci 2020;111:679-86. [PMID: 31828849 DOI: 10.1111/cas.14277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
88 Liu H, Zhang B, Sun Z. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun (Lond) 2020;40:43-59. [PMID: 32067422 DOI: 10.1002/cac2.12005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
89 Yang GJ, Li J, Xu HY, Sun Y, Liu L, Li HS, Yang L, Zhang Y, Li GH, Wang Y. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Lung Cancer 2021;152:39-48. [PMID: 33341538 DOI: 10.1016/j.lungcan.2020.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2019;25:6644-52. [PMID: 31439584 DOI: 10.1158/1078-0432.CCR-19-1126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
91 McAuliffe A, Bindal P, Haley M, Vredenburgh J. Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. J Oncol Pharm Pract 2020;26:206-8. [PMID: 30760168 DOI: 10.1177/1078155219829810] [Reference Citation Analysis]
92 Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clin Lung Cancer 2019;20:e186-94. [PMID: 30563752 DOI: 10.1016/j.cllc.2018.11.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
93 Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB, Chu Q. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer 2021:S0169-5002(21)00429-3. [PMID: 34353680 DOI: 10.1016/j.lungcan.2021.06.002] [Reference Citation Analysis]
94 Long X, Qin T, Lin J. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report. Onco Targets Ther 2020;13:10689-92. [PMID: 33116645 DOI: 10.2147/OTT.S260157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Li M, Zhou CZ, Yang JJ, Lu S, Zheng D, Hu J, Zeng H, Lu Y, Lu KH, Li SA, Mao XR, Han-Zhang H, Lizaso A, Ye JY, Hu CP. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients.Cancer Biol Ther. 2019;20:1097-1104. [PMID: 30990107 DOI: 10.1080/15384047.2019.1595280] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
96 Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer 2021;21:52. [PMID: 33430803 DOI: 10.1186/s12885-020-07765-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Lv L, Liu Z, Liu Y, Zhang W, Jiang L, Li T, Lu X, Lei X, Liang W, Lin J. Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:519073. [PMID: 33224870 DOI: 10.3389/fonc.2020.519073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Shen CI, Ho HL, Yeh YC, Chiu CH, Chou TY. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. J Chin Med Assoc 2020;83:345-9. [PMID: 32101894 DOI: 10.1097/JCMA.0000000000000277] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Yang S, Mao S, Li X, Zhao C, Liu Q, Yu X, Wang Y, Liu Y, Pan Y, Wang C, Gao G, Li W, Xiong A, Chen B, Sun H, He Y, Wu F, Chen X, Su C, Ren S, Zhou C. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Lung Cancer 2020;139:133-9. [PMID: 31786475 DOI: 10.1016/j.lungcan.2019.11.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
100 Wang K, Xu K, Leng X, Han Y, Fang Q. miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR. Technol Cancer Res Treat 2020;19:1533033820945807. [PMID: 32772818 DOI: 10.1177/1533033820945807] [Reference Citation Analysis]